WO2009111948A1 - 3-(4-氨基-1-氧代-1,3-二氢异吲哚-2-基)哌啶-2,6-二酮及其衍生物的盐或盐的多晶型物及其制备和应用 - Google Patents
3-(4-氨基-1-氧代-1,3-二氢异吲哚-2-基)哌啶-2,6-二酮及其衍生物的盐或盐的多晶型物及其制备和应用 Download PDFInfo
- Publication number
- WO2009111948A1 WO2009111948A1 PCT/CN2009/000258 CN2009000258W WO2009111948A1 WO 2009111948 A1 WO2009111948 A1 WO 2009111948A1 CN 2009000258 W CN2009000258 W CN 2009000258W WO 2009111948 A1 WO2009111948 A1 WO 2009111948A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- compound
- formula
- solvate
- polymorph
- acid
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
- C07D209/46—Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
- C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D211/80—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
- C07D211/84—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen directly attached to ring carbon atoms
- C07D211/86—Oxygen atoms
- C07D211/88—Oxygen atoms attached in positions 2 and 6, e.g. glutarimide
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
Definitions
- the present invention relates to a salt of 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)piperidine-2,6-dione with various acids or a solvent of these salts
- 3-(4-Amino-1-oxo-1,3-dihydroisoindol-2-yl)piperidine-2,6-dione (11, wherein Y represents H) has multiple pharmacological effects.
- Compound (II) inhibits the release of inflammatory cytokines in the body and inhibits the formation of new blood vessels, so it can be widely used to treat a variety of diseases including, but not limited to, inflammation, autoimmune disorders, cancer and immune rejection syndrome (see U.S. Patent 5,635,517, 6,281,230, Chinese Patent 200510013292.3).
- Tumor necrosis factor a is a major cytokine released by mononuclear phagocytes in response to immune stimulation.
- Administration of TNFa to animals and humans can cause inflammation, fever, cardiovascular dysfunction, hemorrhage, coagulation, and a series of acute reactions similar to acute infections and shock states.
- Excessive or uncontrolled TNFa in animals or in humans often suggests the following diseases:
- TNFa also plays an important role in bone resorption disorders including arthritis [Betolinni et al. , Nature
- Brainstem malaria is also associated with high levels of TNFa in the blood, which is the most dangerous form of malaria. Sickness, serum TNFa levels are directly related to the condition, and often in patients with acute malaria Occurs [Grau et al., N. Engl. J. Med. 320 (24), 1586-91 (1989)].
- TNFa also plays an important role in chronic pneumonia. Storage of silicon-containing particles in the lungs can cause silicosis. Silicosis is a progressive respiratory failure caused by the fibrosis of the lungs. In animal pathology models, antibodies to TNFa completely block the lung fibrosis process induced by silica dust [Pignet et al., Nature, 344:245-7 (1990)]. Animal experiments have also shown that TNFa is abnormally high in animal serum of pulmonary fibrosis caused by silica dust or asbestos ash [Bissonnette et al., Inflammation 13 (3), 329-339 (1989)].
- TNFa levels in lung tissue of patients with pulmonary nodules are also much higher than in normal people [Baughman et al., J. Lab. Clin. Med. 115(1), 36-42 (1990)]. It is suggested that TNF ⁇ inhibitors are of great significance in the treatment of chronic lung disease and lung injury.
- TNFa The cause of inflammation in Reperfusion Injury may also be due to abnormal levels of TNFa in the patient, and TNF a is considered to be the chief culprit in tissue damage caused by ischemia [Uadderetal., P. AS 87 , 2643 -6 (1990) ]
- TNFa can initiate replication of retroviruses including HIV-1 [Duh et al., Proc. Nat. Acad. Sci., 86, 5974-8 (1989)].
- T_ cells need to be activated before HIV enters T-cells, and once activated T-cells are infected with HIV, these T-cells must remain active to allow the HiV viral gene to be successfully expressed and/or to replicate HIV. .
- Cytokines, especially TNFa play an important role in the expression of HIV proteins regulated by T_ cells or in viral replication. Therefore, inhibition of TNFa production may inhibit the replication of HIV virus in T- cells. [Poll et al., Proc. Nat. Acad. Sci., 87, 782-5 (1990); Monto et al..'; Blood 79, 2670 (1990); Pol l et al., AIDS Res. Human Retrovirus , 191-197 (1992)].
- cAMP regulates many cell-like functions, such as inflammatory reactions, including asthma and inflammation [Lome and Cheng, Drugs of the futune, 17 (9), 799-807, 1992].
- An increase in the cAMP concentration of leukocytes during inflammation inhibits leukocyte activation, followed by the release of inflammatory regulatory factors, including TNFa, which exacerbate inflammation in the patient. Therefore, inhibition of TNFci release can alleviate inflammatory diseases including asthma.
- Li Yingxu et al found that the levels of monocyte synthesis and secretion of tumor necrosis factor in peripheral blood of patients with chronic liver disease were significantly increased, and induced the secretion of other cytokines (such as ⁇ -1 ⁇ , ⁇ -6 and 11-8) and participated in hepatocytes.
- the injury process [Journal of Qiqihar Medical College, 22 (10): 1119-1120, 2001]. Their results are consistent with the findings of Yoshioka et al [Hepatology, 1989, 10: 769-777] and Wang Xin et al [Chinese Journal of Infectious Diseases, 1997, 15 (2): 85-88].
- TNFa inhibitors can significantly inhibit the secretion of TNFa from peripheral blood mononuclear cells in patients with hepatitis, thus laying a molecular pathological basis for the treatment of hepatitis, cirrhosis and liver cancer with TNFa inhibitors.
- TNFa promotes the expression of cell adhesion molecules by promoting the synthesis and release of inflammatory cytokines [Abboud HE Kidney Int. 1993; 43:252-267] [Egido J. et al, Kidney Int. 1993; 43 (suppl 39) : 59-64], and stimulate the synthesis and release of prostaglandin G 2 (PGEJ and platelet activating factor (PAF) [Cammusi G. et al., Kidney Int., 43 (suppl 39): 32-36], making inflammation Cell aggregation and adhesion, microvascular dilatation and permeability enhancement, induction of fever, inflammatory neutrophil increase and hemodynamic changes, resulting in renal cell damage Injury. Many studies suggest that TNF a plays an important role in the pathogenesis and deterioration of nephritis.
- TNF a participates in the regulation of immune function by activating macrophages, immunostimulating T lymphocyte proliferation, regulating B lymphocyte differentiation and enhancing the cytotoxicity of natural killer cells (NK).
- NK natural killer cells
- TNFa levels in patients and/or increasing their cAMP levels is an effective strategy for the treatment of many inflammatory, infectious, immunological or malignant diseases, including but not limited to Sepsis Shock, within Toxic shock, Hemodynamic Shock, Sepsis Syndrom, Post Ischemic Reperfusion Injury, Malaria, Mycobacterial Infection, Meningitis Meningitis), Psoriasis, Congestive Heart Failure, Fibrotic disease, cachexia, transplant rejection, cancer, Autoimmune disease, AIDS Opportunity infection (AIDS), rheumatoid arthritis (RA), hepatitis, nephritis, rheumatoid spondylitis (Rheumatoi d Spondyl itis) and the like.
- Sepsis Shock within Toxic shock, Hemodynamic Shock, Sepsis Syndrom, Post Ischemic Reperfusion Injury, Malaria, Mycobacterial Infection, Meningitis Meningitis), Psoriasis, Con
- Enbrel a soluble TNF receptor, has a good effect on arthritis and psoriasis, suggesting that TNF inhibitors can treat arthritis and psoriasis.
- TNF antagonists can be used to treat diseases that can be treated by controlling TNF levels, including but not limited to arthritis, hepatitis, gastritis, peptic ulcer, oral ulcers, nephritis, rhinitis, bronchitis, COPD ( Chronic obstructive pulmonary disease), pneumonia, tuberculosis, myocarditis, pancreatitis, prostatitis, cervicitis, enteritis, krona syndrome, nerve ending inflammation, myelitis, encephalitis, Parkinson's disease, psoriasis, lupus erythematosus, refractory dermatitis , leprosy, Parkinson's disease, progressive cerebral contracture, Alzheimer's disease, cirrhosis. Therefore, the development of low-toxicity and high-efficiency
- the compound of formula (II) can also inhibit the formation of new blood vessels, and thus can be widely used for treating various diseases including, but not limited to, cancer, including but not limited to bone marrow cancer, leukemia, liver cancer, brain tumor, prostate cancer, gastric cancer, esophageal cancer. , bowel cancer, throat cancer, oral cancer, nasal cancer, bone cancer, cervical cancer, lung cancer, breast cancer, kidney cancer, lymphoma, ovarian cancer, pancreatic cancer, adrenal cancer, mesothelioma, melanoma, myelodysplasia Syndrome.
- cancer including but not limited to bone marrow cancer, leukemia, liver cancer, brain tumor, prostate cancer, gastric cancer, esophageal cancer.
- bowel cancer throat cancer
- oral cancer nasal cancer
- bone cancer cervical cancer
- lung cancer breast cancer
- kidney cancer lymphoma
- pancreatic cancer adrenal cancer
- mesothelioma mesothelioma
- melanoma myel
- the compound (II) is poor in water solubility.
- American Cell Technology Company studied various hydrates and crystal forms of compound (II) (see World Patent WO2005/023192), and together with micronization technology, successfully developed a capsule preparation, which was approved by the FDA.
- oral preparations may not achieve therapeutic drug bioavailability, especially for very low water-soluble drugs such as formula ( ⁇ .) compounds, which can achieve 100% bioavailability for all patients.
- formula ( ⁇ .) compounds which can achieve 100% bioavailability for all patients.
- the compound ( ⁇ ) is not easily reacted with an acid to form a corresponding salt, but is easily reacted with a base to form a metal salt such as a sodium salt, a potassium salt or a calcium salt.
- the compound ( ⁇ ) is unstable under alkaline conditions and is easily hydrolyzed. Thus, no reports on the salt of the compound (II) have been reported so far.
- the preparation of a salt in the form of a free base can not only greatly improve the water solubility of the drug molecule and its oral bioavailability, but also prepare the drug for non-oral administration, such as intravenous administration, muscle. Note, inhalation, and drops are provided.
- the preparation of a free base form of a drug molecule into a salt also provides more options for the preparation of a controlled release formulation.
- the salt-forming form of the drug molecule may have superior stability in processing, processability, and the like.
- the preparation of salt in the form of a free base form of the drug also opens up possibilities for the development of bulk drug purification methods acceptable to national regulatory authorities.
- the salt-preparing drug can be easily recrystallized in a safe solvent typified by water, alcohol, and ketone to obtain a high-quality drug substance product.
- a safe solvent typified by water, alcohol, and ketone
- the preparation of a free base form of a drug molecule into a salt is generally the best choice for the drug substance.
- the inventors When investigating the relationship between the water solubility of the compound of the formula (II) and the pH, the inventors found that the compound of the formula (II) has an improved water solubility under acidic conditions. This reveals that the amino group in (I) can interact with hydrogen ions in XH. The inventors then systematically studied the reaction of the compound of the formula ( ⁇ ) with various inorganic and organic acids, and was consciously surprised to find that the compound of the formula (II) can react with a strong acid to form a salt, but not with a medium-strength acid. And weak acids, such as phosphoric acid, benzoic acid ', succinic acid, oxalic acid, fumaric acid, maleic acid, acetic acid, etc. react to form a salt.
- weak acids such as phosphoric acid, benzoic acid ', succinic acid, oxalic acid, fumaric acid, maleic acid, acetic acid, etc. react to form a salt.
- the present invention discloses a compound of the formula (I), and its preparation and use:
- XH represents a variety of pharmaceutically acceptable strong acids including, but not limited to, hydrochloric acid, hydrobromic acid, sulfuric acid, nitric acid or substituted sulfonic acids of formula (III).
- R represents a C 6 hydrocarbon group, an aromatic ring or a heterocyclic ring
- the hydrocarbon group in the present invention is a saturated branched hydrocarbon group, an unsaturated branched hydrocarbon group, a saturated linear hydrocarbon group, an unsaturated linear hydrocarbon group,
- a saturated ring via a saturated or cyclic hydrocarbon group may be optionally substituted by one or more of F Cl Br N0 2 0H C00H C00R' S0 : , H S0 2 R'S0R' CN C0NR l R 2 , an aromatic ring, an aromatic heterocyclic ring , OR' or NR'R 2 is substituted.
- the aromatic ring in the present invention is a monocyclic aromatic ring or a fused ring aromatic ring, which may be selectively substituted by one or more N0 2 F Cl Br 0H C00H NHC(0)R'NR'R 2 NHR l NH 2 SR 0R'C00R' S0 3 H is substituted.
- the heterocyclic ring in the present invention includes a tetravalent, five-, six-, seven- or eight-membered saturated heterocyclic ring containing one or more hetero atoms such as nitrogen, oxygen, sulfur atoms, an unsaturated heterocyclic ring, an aromatic heterocyclic ring or a fused heterocyclic ring which may be optionally substituted by one or more F NO,, Cl Br 0H C00H NHC(0)R' NR l R 2 N SR'0R'C00R';
- R' R 2 in the present invention respectively denotes a saturated or unsaturated branched or straight-chain hydrocarbon group having 1 to 4 carbon atoms, which may be optionally substituted by one or more of F Cl Br 0H C00H.
- a compound suitable for salt formation with a compound of formula (II) is R represents (where C is a hydrocarbyl group, C3 ⁇ 4CH;, CH 2 CH, CH : t CC CH 2 CH : , CH(CH : i ) 2 CH 2 CH(C ) 2 C(CH :i ), CF, CHF 2 CH 2 F CH 2 CF 3 C CHF 2 CH 2 CH 2 F (3 ⁇ 4C CF, CH.CH.CHF,, CH 2 CH 2 CF, cyclohexyl or cyclopentyl
- a compound which is more suitable to form a salt with a compound of the formula (II) is CH when R represents a d-e hydrocarbon group, CH 2 CH : I C CH 2 CH, CH(CH 3 ) 2 CH 2 CH(CH 3 ) 2 CF 3 CHF 2 CH 2 F CH 2 CF 3 CH 2 CHF 2 CCFCC CF:,;
- a compound of the formula (III) suitable for salt formation with a compound of the formula (II) is when R represents an aromatic ring, and R represents a phenyl group, a 1-naphthyl group, a 2-naphthyl group, a 5-sulfonylnaphthalene-1-one group, Methylphenyl, o-methylphenyl, m-methylphenyl, p-hydroxyphenyl, o-hydroxyphenyl, m-hydroxyphenyl, trifluoromethylphenyl, p-carboxyphenyl, m-carboxyphenyl, adjacent Carboxyphenyl, p-sulfonic acid phenyl, m-sulfonic acid phenyl, o-sulfonic acid phenyl, p-ethylphenyl, o-ethylphenyl, m-ethylphenyl, p-methoxyphenyl,
- the compound of the formula (III) which is suitable for salt formation with the compound of the formula (II) is a compound wherein R represents a heterocyclic ring, and R represents a furan ring, a pyrrole ring, a thiophene ring or a pyridine ring.
- the "strong acid” in the present invention means an organic acid or a mineral acid having a pKa smaller than that of pKal of phosphoric acid.
- the compound of the formula (I) disclosed in the present invention has a water solubility of 4 to 5000 times higher than that of the compound of the formula (?).
- the molar ratio of (II) to XH in the compound of formula (I) may be 1: 0.1-5, and the suitable molar ratio is 1:0.5-2, and the most suitable molar ratio is 1:1 or 2:1.
- the compound of the formula (I) disclosed in the present invention may be in the form of no solvent or may be in a solvated form, especially in the form of a hydrate or an alcoholate.
- the compound of the formula (I) disclosed in the present invention may be used as a single salt or a mixture of several salts.
- the compound of the formula (I) disclosed in the present invention may be in an amorphous form when used, or may be in various crystal forms thereof, or a mixture of these forms.
- the compound of the formula (I) disclosed in the present invention may be in the form of a 5" type or a ? type, or a mixture of ? and type 5.
- the compound of the formula (I) disclosed in the present invention can be produced by the following method:
- Method A Dissolve the compound of formula (II) in a suitable solvent; add XH; control the reaction temperature; place and control temperature.
- Method B dissolving XH in a suitable solvent; adding a compound represented by formula (II); controlling the reaction temperature; placing and controlling temperature.
- Method C the compound of the formula (II) is dissolved in a suitable solvent; XH is dissolved in a suitable solvent; the reaction temperature is controlled; and the temperature is set and controlled.
- the solvent described in the above production method may be any suitable solvent including, but not limited to, a mixture of one or more of water, alcohol, ester, ketone, ether, amide, sulfone or sulfoxide.
- Suitable alcohol, ester, ketone, ether, amide, sulfone, sulfoxide solvents as described in the above preparation methods including but not limited to methanol, ethanol, propanol, isopropanol, acetone, methyl ethyl ketone, diethyl ether, isopropyl Ether, THF (tetrahydrofuran), 1, 4-dioxane, ethyl formate, ethyl acetate, propyl formate, isopropyl formate, methyl acetate, propyl acetate, isopropyl acetate, butyl formate, A mixture of one or more of DMF (N,N-dimethylformamide), DMA ( ⁇ , ⁇ -dimethylacetamide) or DMSO (dimethyl sulfoxide.
- DMF N,N-dimethylformamide
- DMA ⁇ , ⁇ -dimethylacetamide
- DMSO
- the molar ratio of the compound of the formula ( ⁇ ) to hydrazine in the above preparation method may be 1: 0.1-50; the suitable molar ratio is 1: 0.2-10; the most suitable molar ratio is 1: 0.5-2;
- the volatile acid and rhodium may be added in an amount of 10% or more by mole of the compound of the formula (II).
- the reaction temperature in the above preparation method may be -40 to 200 ° C; the suitable temperature is -20 - 100 ° C; the most suitable temperature is 0 - 80 ° C o
- the compound of the formula (I) disclosed in the present invention has a unit dosage range of 0.1 mg to 250 mg; the optimized unit dosage is 1 mg to 100 mg; and the optimal unit dosage is 5 mg to 50 mg.
- the most convenient unit dosage of the compound of the formula (I) disclosed in the present invention is equivalent to the compound of the formula (I), which is equivalent to 5 mg, 10 mg, and 25 mg of the compound of the formula (I).
- the most commonly used unit dosage is the equivalent unit dosage of 10 mg and 25 mg of the compound of formula (II).
- the unit dose used in the present invention means a unit which can be administered to a patient and which is easy to handle and package, i.e., a single dose.
- the indications for the use of the compound of the formula (I) as a pharmaceutically active ingredient are all diseases which are effective in alleviating and treating by reducing the level (concentration) of TNF ci in a patient, including but not limited to inflammatory, infectious, Immune or malignant tumors.
- Specific disease types include, but are not limited to, Sepsis Shock, Endotoxin Shock, Hemodynamic Shock, Sepsis Syndrom, Post-ischemic Reperfusion Injury (Post) Ischemic Reperfusion Injury), Malaria, Mycobacterial Infection, Meningiti s, Psoriasis, Congestive Heart Failure, Fibrotic disease ), cachexia, transplant rejection, cancer, autoimmune disease, Opportunistic Infection in AIDS, leprosy nodular erythema, lupus erythematosus, refractory lupus erythematosus, Beck Chet syndrome, Crohn's disease, myelodysplastic syndrome, rheumatoid arthritis (RA), hepatitis, nephritis, rheumatoid spondylitis (Rheumatoid Spondylitis). Multiple myeloma, thyroid tumor, kidney cancer , prostate cancer, lymphoma, leukemia and
- the compound of the formula (I) disclosed in the present invention can be prepared into tablets, capsules, powders, solution preparations, freeze-dried powder needles, aerosols, sprays, ointments, patches, eye drops, ear drops Or a preparation such as an implant, which is administered by oral administration, injection, inhalation, eye drops, ear drops, transdermal, rectal, vaginal administration or the like.
- An advantage of the compound of the formula (I) disclosed in the present invention is that it can be prepared for use as an injection.
- Another advantage of the compounds of formula (I) disclosed herein is that they can be prepared for use as sustained release formulations.
- the compounds of formula (I) disclosed herein may be used in combination with other suitable pharmaceutical compositions, including but not limited to: obl imersen (Genasense®), remicade, docetaxel, celecoxib, melphalan, ground Dexamethasone, steroids, gemcitabine, cisplatin, temozolomide, etoposide, cyclophosphamide, carboplatin, procarbazine, carustine, tamoxifen, topotecan, methotrexate, Arisa®, paclitaxel, taxotere, fluorouracil, leucovorin, irinotecan, Xeloda, CPT-11, interferon alpha, PEGylated interferon alpha, vinblastine, doxorubicin, vincristine, sulphate Lin acid, prednisone.
- the compound of the formula (I) disclosed in the present invention can also be used in combination with a
- the present invention includes the use of a compound of the formula (I) or a solvate thereof, wherein hydrazine represents various pharmaceutically acceptable 3 ⁇ 4 acids, characterized in that the application is for the preparation of a therapeutic effect by inhibiting inflammatory factors. Those drugs that are ill or physiologically abnormal.
- the diseases or physiological abnormalities which can be achieved by inhibiting inflammatory factors according to the present invention may be arthritis, hepatitis, gastritis, peptic ulcer, oral ulcer, nephritis, rhinitis, bronchitis, COPD, pneumonia, tuberculosis, myocarditis, pancreas Inflammation, prostatitis, cervicitis, enteritis, krona syndrome, nerve ending inflammation, myelitis, encephalitis, Parkinson's disease, psoriasis, lupus erythematosus, refractory dermatitis, leprosy, Parkinson's disease, progressive brain atrophy Symptoms, Alzheimer's disease, cirrhosis.
- the present invention also encompasses the use of a compound of the formula (I) or a solvate thereof as a neovascularization inhibitor, wherein XH represents various pharmaceutically acceptable strong acids, characterized in that the application is prepared for treatment by inhibition Newborn angiogenesis drugs that achieve therapeutic effects.
- the diseases according to the present invention which are effective in inhibiting neovascularization are cancer, including but not limited to bone marrow cancer, leukemia, liver cancer, brain tumor, prostate cancer, gastric cancer, esophageal cancer, intestinal cancer, throat cancer, oral cancer, Nasal cancer, bone cancer, cervical cancer, lung cancer, breast cancer, kidney cancer, lymphoma, ovarian cancer, pancreatic cancer, adrenal cancer, mesothelioma, melanoma, myelodysplastic syndrome, bladder cancer, head and neck cancer, blood cancer , neuroblastoma, angioendothelioma, rectal cancer.
- cancer including but not limited to bone marrow cancer, leukemia, liver cancer, brain tumor, prostate cancer, gastric cancer, esophageal cancer, intestinal cancer, throat cancer, oral cancer, Nasal cancer, bone cancer, cervical cancer, lung cancer, breast cancer, kidney cancer, lymphoma, ovarian cancer, pancreatic cancer, adrenal cancer, mesothelioma,
- the present invention also discloses polymorphs of the solvate of the compound of formula (I) or the compound of formula (I):
- XH represents a polymorph (IA) of a compound of the formula (I) or a solvate of the compound of the formula (I) in the case of sulfuric acid
- XH represents a polymorph (IB) of a compound of the formula (I) or a solvate of a compound of the formula (I) in the case of sulfuric acid
- XH represents a polymorph ( ⁇ ) of a compound of the formula (I) or a solvate of a compound of the formula (I) in the case of nitric acid
- XH represents benzenesulfonate.
- XH represents a polymorph (IVB) of a compound of the formula (I) or a solvate of the compound of the formula (I) in the case of p-toluenesulfonic acid,
- XH represents a polymorph (VA) of a compound of the formula (I) or a solvate of the compound of the formula (I) in the case of hydrobromic acid,
- XH represents a polymorph (VIA) of a compound of the formula (I) or a solvate of the compound of the formula (I) in the case of methanesulfonic acid,
- XH represents a polymorph (VIB) of a compound of the formula (I) or a solvate of the compound of the formula (I) in the case of methanesulfonic acid,
- XH represents a polymorph (VIIA) of a compound of the formula (I) or a solvate of the compound of the formula (I) in the case of hydrochloric acid,
- the invention also provides a process for the preparation of a polymorph of a solvate of a compound of formula (I) or a compound of formula (I):
- Method B Dissolve XH in a suitable solvent; add the compound of formula ( ⁇ ); stir and filter.
- Process C The compound of the formula (II) is dissolved in a suitable solvent; XH is dissolved in a suitable solvent and added to a solution containing the compound of the formula (II); stirred and filtered.
- the solvent described in the above production method may be any suitable solvent including, but not limited to, a mixture of one or more of water, alcohol, ester, ketone, ether, amide, sulfone or sulfoxide.
- Suitable alcohol, ester, ketone, ether, amide, sulfone, sulfoxide solvents as described in the above preparation methods including but not limited to methanol, ethanol, propanol, isopropanol, acetone, methyl ethyl ketone, diethyl ether, isopropyl Ether, THF (tetrahydrofuran), 1,4-two palms (hexacyclic, ethyl formate, ethyl acetate, propyl formate, isopropyl formate, methyl acetate, propyl acetate, isopropyl acetate, butyl formate)
- DMF ⁇ , ⁇ -dimethylformamide
- DMA ⁇ , ⁇ -dimethylacetamide
- DMSO dimethyl sulfoxide
- the molar ratio of the compound of the formula ( ⁇ ) to hydrazine in the above preparation method may be 1: 0.1-50; the suitable molar ratio is 1: 0.2-10; the most suitable molar ratio is 1: 0.5-2;
- the volatile acid may be added in an amount of 10% or more by mole of the compound of the formula (II).
- the reaction temperature in the above preparation method may be -40 to 200 ° C ; the suitable temperature is -20 to 100 ° C ; and the most suitable temperature is 0 to 80 V.
- the polymorph of the solvate of the compound of the formula (I) or the compound of the formula (I) disclosed in the present invention is used in a dosage range of 0.1 mg to 250 mg; the optimized unit dosage is 1 mg. 100 mg; The optimal unit dosage is: 5 mg to 50 mg.
- the most convenient unit dosage of the compound of the formula (I) or the solvate of the compound of the formula (I) disclosed in the present invention is 5 mg, 10 mg, 25 mg of the formula (II).
- the compound is equivalently used in the unit dosage of the compound of the formula (I), and the most commonly used unit dosage is an equivalent unit dosage of 10 mg and 25 mg of the compound of the formula (II).
- the unit dosage used in the present invention refers to a unit that can be administered to a patient and is easy to handle and package, that is, a single agent.
- the indications for the use of the polymorph of the compound of formula (I) or the solvate of the compound of formula (I) as a pharmaceutically active ingredient are all effective in reducing the level (concentration) of TNF ci in a patient and Those diseases treated include, but are not limited to, inflammatory, infectious, immunological or malignant diseases.
- Specific disease types include, but are not limited to, sepsis Sepsy Shock, Endotoxin Shock, Hemodynamic Shock, Sepsis Syndrom, Post Ischemic Reperfusion Injury, Malaria, Mycobacterium Mycobacterial Infection, Meningitis, Psoriasis, Congestive Heart Failure, Fibroti c disease, cachexia, transplant rejection, cancer, autoimmunity Autoimmune disease, Opportunistic Infection in AIDS, Leprosy nodular erythema, Lupus erythematosus, refractory lupus erythematosus, Behcet's syndrome, Crohn's disease, Myelodysplastic syndrome , rheumatoid arthritis (RA), hepatitis, nephritis, rheumatoid spondylitis (Rheumatoid Spondylitis). Multiple myeloma, thyroid tumor, kidney cancer, prostate cancer, lymphoma,
- the polymorph of the compound of the formula (I) or the solvate of the compound of the formula (I) disclosed in the present invention can be prepared by oral administration, injection, inhalation, eye drop, ear drop, transdermal, rectal or vaginal administration.
- Formulations for administration by drugs and the like including but not limited to injections, injections, powder injections, freeze-dried powder injections, tablets, capsules, dropping pills, sprays, eye drops, ear drops, patches, ointments, An implant, a sustained release formulation or a solution formulation.
- the polymorph of the solvate of the compound of formula (I) or the compound of formula (I) disclosed herein may be used in combination with a suitable other pharmaceutical composition, including but not limited to: oblimersen (Genasense®;), remicade , docetaxel, celecoxib, melphalan, dexamethasone, steroids, gemcitabine, cisplatin, temozolomide, etoposide, cyclophosphamide', carboplatin, procarbazine, caromos Tetamine, Tamoxifen, Topotecan, Methotrexate, Arisa®, Paclitaxel, Taxotere; Fluorouracil, Folinic Acid, Irinotecan, Xeloda, CPT-11, Interferon A, PEGylation One or more of interferon alpha, vinblastine doxorubicin, vincristine, sulindac or prednisone.
- a suitable other pharmaceutical composition including
- the invention comprises the use of a polymorph of a solvate of a compound of formula (I) or a compound of formula (I), wherein hydrazine represents a variety of pharmaceutically acceptable strong acids, characterized in that said application is preparation A medicament for treating those diseases or physiological abnormalities which can be achieved by inhibiting inflammatory factors.
- Those diseases or physiological abnormalities which can be achieved by inhibiting inflammatory factors according to the present invention include, but are not limited to, arthritis, hepatitis, gastritis, peptic ulcer, oral ulcer, nephritis, rhinitis, bronchitis, COPD, pneumonia, tuberculosis, myocarditis. , pancreatitis, prostatitis, cervicitis, enteritis, krona syndrome, nerve ending inflammation, myelitis, encephalitis, Parkinson's disease, psoriasis, lupus erythematosus, refractory dermatitis, leprosy, Parkinson's disease, progressive Brain atrophy, Alzheimer's disease or cirrhosis.
- the present invention also encompasses the use of a polymorph of a solvate of a compound of the formula (I) or a compound of the formula (I) as a neovascularization inhibitor, wherein XH represents various pharmaceutically acceptable strong acids, the characteristics thereof
- XH represents various pharmaceutically acceptable strong acids
- the diseases according to the present invention which are effective in inhibiting neovascularization are cancer, including but not limited to bone marrow cancer, leukemia, liver cancer, brain tumor, prostate cancer, gastric cancer, esophageal cancer, intestinal cancer, throat cancer, oral cancer, Nasal cancer, bone cancer, cervical cancer, lung cancer, breast cancer, kidney cancer, lymphoma, ovarian cancer, pancreatic cancer, adrenal cancer, mesothelioma, melanoma, myelodysplastic syndrome, bladder cancer, head and neck cancer, blood cancer , neuroblastoma, angioendothelioma or rectum Cancer.
- cancer including but not limited to bone marrow cancer, leukemia, liver cancer, brain tumor, prostate cancer, gastric cancer, esophageal cancer, intestinal cancer, throat cancer, oral cancer, Nasal cancer, bone cancer, cervical cancer, lung cancer, breast cancer, kidney cancer, lymphoma, ovarian cancer, pancreatic cancer, adrenal cancer, mesothelioma,
- Figure 1 Polymorph of the solvate of the compound of formula (I) or the solvate of compound of formula (I) when XH represents sulfuric acid
- Figure 2 Polymorph of the solvate of the compound of formula (I) or the solvate of compound of formula (I) when XH represents sulfuric acid
- Figure 3 Polymorph of the solvate of the compound of formula (I) or the solvate of compound of formula (I) when XH represents sulfuric acid
- Figure 4 XH powder diffraction pattern of the polymorph (IIA) of the compound of formula (I) or the solvate of compound of formula (I) when XH is represented by nitric acid,
- Figure 5 X powder diffraction pattern of the polymorph (IIIA) of the compound of the formula (I) or the solvate of the compound of the formula (I) when XH represents benzenesulfonic acid,
- Figure 6 X powder diffraction pattern of the polymorph ( ⁇ ) of the solvate of the compound of the formula (I) or the compound of the formula (I) when XH represents benzenesulfonic acid,
- Figure 7 X powder diffraction pattern of the polymorph (IVA) of the compound of the formula (I) or the solvate of the compound of the formula (I) when XH represents p-toluenesulfonic acid,
- Figure 8 X powder diffraction pattern of the polymorph (IVB) of the compound of the formula (I) or the solvate of the compound of the formula (I) when XH represents p-toluenesulfonic acid,
- Figure 9 X powder diffraction pattern of the polymorph (VA) of the compound of formula (I) or the solvate of compound of formula (I) when XH represents hydrobromic acid,
- Figure 10 X powder diffraction pattern of the polymorph (VIA) of the compound of the formula (I) or the solvate of the compound of the formula (I) when XH represents methanesulfonic acid,
- Figure 11 X powder diffraction pattern of the polymorph (VIB) of the compound of the formula (I) or the solvate of the compound of the formula (I) when XH represents methanesulfonic acid,
- X powder represents the X powder diffraction pattern of the polymorph (VIIA) of the compound of the formula (I) or the solvate of the compound of the formula (I) in the case of hydrochloric acid,
- Figure 13 Infrared absorption spectrum of the polymorph (IB) of the solvate of the compound of formula (I) or the compound of formula (I) when XH represents sulfuric acid,
- Figure 14 Infrared absorption spectrum of the polymorph (IIIB) of the solvate of the compound of the formula (I) or the compound of the formula (I) when XH represents benzenesulfonic acid,
- Figure 15 Infrared absorption spectrum of the polymorph (IVA) of the solvate of the compound of the formula (I) or the compound of the formula (I) when XH represents p-toluenesulfonic acid,
- XH represents the infrared absorption spectrum of the polymorph (VI1A) of the compound of the formula (I) or the solvate of the compound of the formula (I) in the case of hydrochloric acid,
- the compound (518 mg) represented by (11, wherein Y represents H) was added to 30 mL of absolute ethanol to dissolve (11, wherein Y represents H) in an absolute ethanol solution, and an equimolar organic weak acid was added and 10 mL of absolute ethanol was added.
- an organic acid in ethanol solution was added to (11, where Y is H) in an anhydrous ethanol solution heated to reflux in an oil bath, a small amount of water was added to make the system clear, after refluxing for 30 minutes, the mixture was taken out and stirred at room temperature to precipitate a solid. Stirring was continued for 4 hours, suction filtration, and the filter cake was vacuum dried for 10 hours.
- HNMR confirmed the starting material (11, where Y represents H) (or a material containing 1 crystal water (11, where Y represents H))
- Example 39 Preparation of polymorph (VIIA) 'In a 250 ml three-necked flask, 1.038 g of 3-(4-aminosodium oxy-1,3-1,3-dihydroisoindol-2-yl)piperidine-2 was added. The 6-diketone and 35 ml of tetrahydrofuran were introduced into the HC1 gas under stirring at room temperature for 1 hour, stirred at room temperature, and suction filtered.
- sample solutions of each example were characterized by ultraviolet spectral scanning in the wavelength range of 190-900 nm, and the maximum absorbance was set to 2. All the analytes at 304 nm had the same uniform absorption peak, and there were other absorptions in the 205-190TM region. Bee, but
- the peak shape is slightly different, and the maximum absorption peak wavelength is also different, so the fixed wavelength of the concentration-absorbance measurement is determined to be 304 nm.
- the solubility of Example 7 was found to be greater than lg/mL, so that the compound was selected as the concentration-absorbance standard curve.
- Example 7 Take Example 7 (279.26 mg) and add distilled water to dissolve in a 100 ml volumetric flask. At this time, the solution concentration is 2.793 mg/mL; respectively, take the above solution 1 mL, 2 mL, 3 mL, 5 mL, respectively, in a 50 ml volumetric flask.
- the concentration of the solution is 0. 056 mg / mL, 0. 112rag / mL, 0. 167mg / mL, 0. 279mg / mL, the standard curve of the absorbance - concentration coordinates, Y 2 correlation coefficient is 0. 99951 (see attached drawing).
Description
Claims
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US12/880,983 US20110060010A1 (en) | 2008-03-13 | 2010-09-13 | Salts of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)piperidine-2,6-dione and derivatives thereof, or polymorphs of salts, process for preparing same and use thereof |
US13/675,767 US20130131112A1 (en) | 2008-03-13 | 2012-11-13 | Salts of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)piperidine-2,6-dione and derivatives thereof, or polymorphs of salts, process for preparing same and use thereof |
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN200810052422 | 2008-03-13 | ||
CN200810052422.8 | 2008-03-13 | ||
CN200910118977.2 | 2009-03-11 | ||
CN200910118977.2A CN101531653B (zh) | 2008-03-13 | 2009-03-11 | 3-(4-氨基-1-氧代-1,3-二氢异吲哚-2-基)哌啶-2,6-二酮及其衍生物的盐或盐的多晶型物及其制备和应用 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
US12/880,983 Continuation US20110060010A1 (en) | 2008-03-13 | 2010-09-13 | Salts of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)piperidine-2,6-dione and derivatives thereof, or polymorphs of salts, process for preparing same and use thereof |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2009111948A1 true WO2009111948A1 (zh) | 2009-09-17 |
Family
ID=41064740
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2009/000258 WO2009111948A1 (zh) | 2008-03-13 | 2009-03-11 | 3-(4-氨基-1-氧代-1,3-二氢异吲哚-2-基)哌啶-2,6-二酮及其衍生物的盐或盐的多晶型物及其制备和应用 |
Country Status (2)
Country | Link |
---|---|
CN (1) | CN101531653B (zh) |
WO (1) | WO2009111948A1 (zh) |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7855217B2 (en) | 2003-09-04 | 2010-12-21 | Celgene Corporation | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
US7863451B2 (en) | 2004-09-03 | 2011-01-04 | Celgene Corporation | Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines |
WO2011018101A1 (en) * | 2009-08-12 | 2011-02-17 | Synthon B.V. | Lenalidomide salts |
US7994327B2 (en) | 2005-06-30 | 2011-08-09 | Celgene Corporation | Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds |
WO2011111053A1 (en) | 2010-03-08 | 2011-09-15 | Natco Pharma Limited | Anhydrous lenalidomide form-i |
Families Citing this family (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102060842B (zh) * | 2009-11-02 | 2013-05-08 | 南京卡文迪许生物工程技术有限公司 | 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物 |
CN101696205B (zh) | 2009-11-02 | 2011-10-19 | 南京卡文迪许生物工程技术有限公司 | 3-(取代二氢异吲哚-2-基)-2,6-哌啶二酮多晶型物和药用组合物 |
Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5874448A (en) * | 1997-11-18 | 1999-02-23 | Celgene Corporation | Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels |
CN1575174A (zh) * | 2000-11-14 | 2005-02-02 | 细胞基因公司 | 有药学活性的异吲哚啉衍生物 |
WO2007005972A1 (en) * | 2005-06-30 | 2007-01-11 | Celgene Corporation | Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds |
Family Cites Families (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6281230B1 (en) * | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
US5635517B1 (en) * | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
CA2624949C (en) * | 1996-07-24 | 2011-02-15 | Celgene Corporation | Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and -1-oxoisoindolines and method of reducing tnf.alpha. levels |
US5955476A (en) * | 1997-11-18 | 1999-09-21 | Celgene Corporation | Substituted 2-(2,6-dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing inflammatory cytokine levels |
-
2009
- 2009-03-11 CN CN200910118977.2A patent/CN101531653B/zh active Active
- 2009-03-11 WO PCT/CN2009/000258 patent/WO2009111948A1/zh active Application Filing
Patent Citations (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5874448A (en) * | 1997-11-18 | 1999-02-23 | Celgene Corporation | Substituted 2-(2,6 dioxo-3-fluoropiperidin-3-yl)-isoindolines and method of reducing TNFα levels |
CN1575174A (zh) * | 2000-11-14 | 2005-02-02 | 细胞基因公司 | 有药学活性的异吲哚啉衍生物 |
WO2007005972A1 (en) * | 2005-06-30 | 2007-01-11 | Celgene Corporation | Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds |
Cited By (19)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US9365538B2 (en) | 2003-09-04 | 2016-06-14 | Celgene Corporation | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
US11655232B2 (en) | 2003-09-04 | 2023-05-23 | Celgene Corporation | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
US7977357B2 (en) | 2003-09-04 | 2011-07-12 | Celgene Corporation | Polymorphic forms of 3-(4-amino-1-oxo-1, 3 dihydro-isoindo1-2-yl)-piperidine-2,6-dione |
US7855217B2 (en) | 2003-09-04 | 2010-12-21 | Celgene Corporation | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
US11136306B2 (en) | 2003-09-04 | 2021-10-05 | Celgene Corporation | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-peridine-2,6-dione |
US8058443B2 (en) | 2003-09-04 | 2011-11-15 | Celgene Corporation | Processes for preparing polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-YL))-piperidine-2,6-dione |
US8143286B2 (en) | 2003-09-04 | 2012-03-27 | Celgene Corporation | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione) |
US10590104B2 (en) | 2003-09-04 | 2020-03-17 | Celgene Corporation | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
US9371309B2 (en) | 2003-09-04 | 2016-06-21 | Celgene Corporation | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
US9353080B2 (en) | 2003-09-04 | 2016-05-31 | Celgene Corporation | Polymorphic forms of 3-(4-amino-1-oxo-1,3 dihydro-isoindol-2-yl)-piperidine-2,6-dione |
US7863451B2 (en) | 2004-09-03 | 2011-01-04 | Celgene Corporation | Processes for the preparation of substituted 2-(2,6-dioxopiperidin-3-yl)-1-oxoisoindolines |
US7994327B2 (en) | 2005-06-30 | 2011-08-09 | Celgene Corporation | Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds |
US8785644B2 (en) | 2005-06-30 | 2014-07-22 | Celgene Corporation | Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds |
US9394274B2 (en) | 2005-06-30 | 2016-07-19 | Celgene Corporation | Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds |
US9822093B2 (en) | 2005-06-30 | 2017-11-21 | Celgene Corporation | Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds |
US10266514B2 (en) | 2005-06-30 | 2019-04-23 | Celgene Corporation | Processes for the preparation of 4-amino-2-(2,6-dioxopiperidin-3-yl)isoindoline-1,3-dione compounds |
US8686153B2 (en) | 2009-08-12 | 2014-04-01 | Synthon B.V. | Lenalidomide salts |
WO2011018101A1 (en) * | 2009-08-12 | 2011-02-17 | Synthon B.V. | Lenalidomide salts |
WO2011111053A1 (en) | 2010-03-08 | 2011-09-15 | Natco Pharma Limited | Anhydrous lenalidomide form-i |
Also Published As
Publication number | Publication date |
---|---|
CN101531653A (zh) | 2009-09-16 |
CN101531653B (zh) | 2014-07-09 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CN106029659B (zh) | 谷氨酰胺酶抑制剂 | |
KR101970837B1 (ko) | 항바이러스제로서의 피라졸로[1,5-a]피리미딘 | |
CN104202984B (zh) | Wnt信号通路的吲唑抑制剂及其治疗应用 | |
TWI643858B (zh) | 結晶型(8S,9R)-5-氟-8-(4-氟苯基)-9-(1-甲基-1H-1,2,4-三唑-5-基)-8,9-二氫-2H-吡啶并[4,3,2-de]呔-3(7H)-酮甲苯磺酸鹽 | |
WO2020259432A1 (zh) | Kras-g12c抑制剂 | |
WO2009111948A1 (zh) | 3-(4-氨基-1-氧代-1,3-二氢异吲哚-2-基)哌啶-2,6-二酮及其衍生物的盐或盐的多晶型物及其制备和应用 | |
TW201912639A (zh) | Shp2之八氫環戊烷并[c]吡咯別構抑制劑 | |
AU2016365676A1 (en) | 2-phenyl-3-(piperazinomethyl)imidazo[1,2-a]pyridine derivatives as blockers of TASK-1 and TASK-2 channels, for the treatment of sleep-related breathing disorders | |
AU2017258193A1 (en) | Isoquinolin-3-yl carboxamides and preparation and use thereof | |
JP5319284B2 (ja) | 誘導物及びその各種薬学的に受容可能な塩、5H−チエノ[3,4−c]ピロール−4,6ジオン誘導物、その調整方法、その使用 | |
WO2017023975A1 (en) | 3-(1h-pyrrolo[2,3-c]pyridin-2-yl)-1h-pyrazolo[3,4-c]pyridines and therapeutic uses thereof | |
JP2010532380A5 (zh) | ||
BR112016012734B1 (pt) | Composto de 2-amino-6-flúor-n-[5-flúor-piridin-3-il]pirazol[1,5-a]pirimidin-3-carboxamida, formas sólidas, composição, seu uso e processo para a preparação do referido composto | |
TW201210592A (en) | Substituted 5-fluoro-1H-pyrazolopyridines and their use | |
WO2001083456A1 (fr) | Derives d'heteroaryle condenses | |
WO2003074525A1 (fr) | Compose heterocyclique azote | |
TW200914443A (en) | Process for preparing substituted quinazolinyl furanaldehyde | |
CZ305220B6 (cs) | 1-[4-(5-kyanindol-3-yl)butyl]-4-(2-karbamoylbenzofuran-5-yl)piperazin hydrochlorid monohydrát v krystalické formě V, způsoby jeho přípravy a léčivo s jeho obsahem | |
WO1985003077A1 (en) | Purine derivatives, process for their preparation, and medicinal composition containing same | |
CN107207486A (zh) | 用于抑制布罗莫结构域和末端外蛋白质的方法和组合 | |
WO2016009297A1 (en) | Pyridine derivatives as muscarinic m1 receptor positive allosteric modulators | |
US10947225B2 (en) | Phosphotidylinositol 3-kinase inhibitors | |
CN105566321A (zh) | 杂芳化合物及其在药物中的应用 | |
JP2008521854A (ja) | 新規ピリドチエノピリミジン誘導体 | |
US20130131112A1 (en) | Salts of 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)piperidine-2,6-dione and derivatives thereof, or polymorphs of salts, process for preparing same and use thereof |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 09720627 Country of ref document: EP Kind code of ref document: A1 |
|
WPC | Withdrawal of priority claims after completion of the technical preparations for international publication |
Ref document number: 200910118977.2 Country of ref document: CN Date of ref document: 20100804 Free format text: WITHDRAWN AFTER TECHNICAL PREPARATION FINISHED |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 09720627 Country of ref document: EP Kind code of ref document: A1 |